Explore the words cloud of the JPI-EC-AMR project. It provides you a very rough idea of what is the project "JPI-EC-AMR" about.
The following table provides information about the project.
Coordinator |
VETENSKAPSRADET - SWEDISH RESEARCH COUNCIL
Organization address contact info |
Coordinator Country | Sweden [SE] |
Project website | http://www.jpiamr.eu |
Total cost | 23˙812˙500 € |
EC max contribution | 7˙858˙116 € (33%) |
Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
Code Call | H2020-HCO-2015 |
Funding Scheme | ERA-NET-Cofund |
Starting year | 2015 |
Duration (year-month-day) | from 2015-11-01 to 2020-10-31 |
Take a look of project's partnership.
Antibiotic resistance is a global problem. It is considered by the World Health Organization as one of the three greatest threats to human health for the next decades. ’Enhanced coordination across national boundaries is needed to accelerate the efforts to tackle this grand challenge. Such synergies have been created among 19 countries in Europe and beyond through the EU JPI on Antimicrobial Resistance (JPIAMR). JPIAMR has developed a Strategic Research Agenda (SRA) which defines the strategic and scientific priorities benefiting from co-ordination and co-operation at the European level and mobilised national funds for two joint transnational calls (JTC) 2014 and 2015 based on this. In the ERA-NET Cofund JPI-EC-AMR, an additional € 23 million of national funds will be combined with a highly incentivising EC top-up fund to support a new transnational research programme. The aim of this programme is to unravel the complex dynamics of selection and transmission of antimicrobial resistance (AMR) according to the One Health concept. A multidisciplinary approach is necessary to identify and characterise the determinants that contribute to the spread of resistance at genetic, bacterial, animal, human, societal, and environmental levels, in order to provide scientific knowledge to design and evaluate cost-effective strategies that can decrease transmission of AMR in society. JPI-EC-AMR will launch additional JTCs without EC co-funding under the framework of the SRA. and perform additional joint actions in close collaboration with JPIAMR actions. JPI-EC-AMR will provide a better, quantitative understanding of drug-resistant bacteria in animals, foods, and the environment and to what extent they contribute to the burden of antibiotic-resistant infections in humans. Research in this area is crucial in order to provide the robust scientific evidence needed to make informed decisions regarding interventions and policy measures in hospital, community, and agricultural settings.
Adopted ranking list of the evaluated full proposals with funding recommendation | Documents, reports | 2020-02-25 12:56:37 |
Publication of JPI-EC-AMR co-funded call | Websites, patent fillings, videos etc. | 2020-02-25 12:56:37 |
Completed and approved final call text and all related documents | Documents, reports | 2020-02-25 12:56:37 |
Description of the electronic submission tool | Documents, reports | 2020-02-25 12:56:37 |
Take a look to the deliverables list in detail: detailed list of JPI-EC-AMR deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "JPI-EC-AMR" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "JPI-EC-AMR" are provided by the European Opendata Portal: CORDIS opendata.
CeLac and European consortium for a personalized medicine approach to Gastric Cancer
Read MoreEvaluation of Dyadic Psychoeducational Interventions for People with Advanced Cancer and their Informal Caregivers (DIAdIC): An international randomized controlled trial
Read More